HIMS explosive catalyst puts squeeze back on the table:

TradingView2026/03/11 18:42

By:TradingView

Current Price: 15.74 (Analysis was generated on Monday Morning)

Direction: LONG

Confidence level: 68%(Several professional traders highlighted a major partnership catalyst, lawsuit resolution, and very high short interest, while X sentiment is mixed but not strongly opposing the upside.)

Targets
Target 1: 16.90
Target 2: 17.80

Stop Levels
Stop 1: 14.90
Stop 2: 14.30

Key Insights:
Here’s what’s driving this trade. Multiple professional traders highlighted the renewed partnership with Novo Nordisk as a game‑changer. The market reacted immediately with an after‑hours move of roughly 40%, which tells me this wasn’t a minor headline — it forced positioning changes. On top of that, traders emphasized that the legal overhang was removed when the lawsuit was dropped, clearing a big source of uncertainty that had kept buyers on the sidelines.

Another key point traders kept coming back to is short interest. Estimates around 39% of the float being sold short mean HIMS doesn’t need perfect news to keep moving higher — it just needs price to hold and grind up. That’s often enough to pressure shorts into covering, especially during the week following a catalyst. X chatter is more cautious, but it hasn’t shown aggressive selling pressure, which matters.

Recent Performance:
You can see all of this directly in the price action. HIMS went from being compressed and ignored to exploding higher almost overnight. Since that surge, price has been consolidating rather than giving everything back. That behavior usually tells me buyers are still present and shorts haven’t fully escaped yet. For a weekly trade, that’s exactly the kind of structure I want to see.

Expert Analysis:
Several traders noted that even after the spike, HIMS is still holding key technical areas rather than collapsing. Debt concerns were mentioned, but they were clearly secondary to the partnership and short‑squeeze dynamics for short‑term trading. When I put this together, I see a stock that’s no longer trading purely on fundamentals — it’s trading on positioning and momentum, which can dominate for days at a time.

News Impact:
The Novo Nordisk partnership revival is the headline doing the heavy lifting here. The fact that this comes alongside the lawsuit being dropped amplifies its impact. This kind of news tends to attract both momentum traders and funds that had been waiting for clarity. That flow can easily carry into the current trading week, even if volatility stays high.

Trading Recommendation:
Here’s my take. I’m staying LONG on HIMS for a short‑term trade this week, looking for continuation toward $16.90 first and $17.80 if momentum accelerates. I’d manage risk tightly with stops at $14.90 and $14.30 because this is still a volatile name. Confidence sits at 68% — strong trader conviction and catalysts support the upside, while mixed social chatter keeps me disciplined on risk.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

HIMS explosive catalyst puts squeeze back on the table:

You may also like

Trending news

Crypto prices